|Bid||4,352.00 x 10000|
|Ask||4,548.00 x 30000|
|Day's Range||4,418.50 - 4,480.50|
|52 Week Range||3,996.00 - 5,520.00|
|PE Ratio (TTM)||16.66|
|Dividend & Yield||2.79 (4.93%)|
|1y Target Est||N/A|
AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.
While AstraZeneca has suffered a serious setback in the hot field of cancer immunotherapy, a host of comparative minnows, undeterred, are pressing ahead with allied technologies that promise millions in ...
The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.